In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Srinivas Murthy, Dr. Thomas Hills, and Dr. Lindsay Berry about the REMAP-CAP trial results on oseltamivir in critically ill influenza patients.

In this episode of "In the Interim…", Dr. Scott Berry leads a comprehensive discussion of the ICECAP trial results with four Principal Investigators.

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Elizabeth Lorenzi systematically examine the analytic pitfalls in recent acute ischemic stroke trials, especially the implications of violating the proportional odds assumption on the modified Rankin Scale.

Not all interim analyses in clinical trials require alpha adjustment; penalties depend entirely on the pre-specified adaptive action, not the simple act of reviewing data.

In this episode of "In the Interim…", Dr. Scott Berry challenges the widely held belief that any interim look at trial data obligates an alpha adjustment.

In this episode of "In the Interim…," Dr. Scott Berry interviews Tim Berry, co-founder of Blend360, detailing a career that demonstrates the practical application of statistical and analytical methods within large-scale business environments.